Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Front Cardiovasc Med ; 9: 925816, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-36017084

RESUMEN

Atherosclerotic cardiovascular disease is a growing threat among cancer patients. Not surprisingly, cancer-targeting therapies have been linked to metabolic dysregulation including changes in local and systemic lipid metabolism. Thus, tumor development and cancer therapeutics are intimately linked to cholesterol metabolism and may be a driver of increased cardiovascular morbidity and mortality in this population. Chemotherapeutic agents affect lipid metabolism through diverse mechanisms. In this review, we highlight the mechanistic and clinical evidence linking commonly used cytotoxic therapies with cholesterol metabolism and potential opportunities to limit atherosclerotic risk in this patient population. Better understanding of the link between atherosclerosis, cancer therapy, and cholesterol metabolism may inform optimal lipid therapy for cancer patients and mitigate cardiovascular disease burden.

2.
JACC Heart Fail ; 10(8): 571-580, 2022 08.
Artículo en Inglés | MEDLINE | ID: mdl-35902161

RESUMEN

BACKGROUND: With rising United States health care expenditure, estimating current spending for patients with heart failure (HF) informs the value of preventative health interventions. OBJECTIVES: The purpose of this study was to estimate current health care expenditure growth for patients with HF in the United States. METHODS: The authors pooled MEPS (Medical Expenditure Panel Survey) data from 2009-2018 to calculate total HF-related expenditure across clinical settings in the United States. A 2-part model adjusted for demographics, comorbidities, and year was used to estimate annual mean and incremental expenditures associated with HF. RESULTS: In the United States, an average of $28,950 (2018 inflation-adjusted dollars) is spent per year for health care-related expenditure for individuals with HF compared with $5,727 for individuals without HF. After adjusting for demographics and comorbidities, a diagnosis of HF was associated with $3,594 in annual incremental expenditure compared with those without HF. HF-related expenditure increased from $26,864 annual per person in 2009-2010 to $32,955 in 2017-2018, representing a 23% rise over 10 years. In comparison, expenditure on myocardial infarction, type 2 diabetes mellitus, and cancer grew by 16%, 28%, and 16%, respectively. Most of the cost was related to hospitalization: $12,569 per year. Outpatient office-based care and prescription medications saw the greatest growth in cost over the period, 41% and 24%, respectively. Estimated incremental national expenditure for HF per year was $22.3 billion; total annual expenditure for adults with HF was $179.5 billion. CONCLUSIONS: HF is a costly condition for which expenditure is growing faster than that of other chronic conditions.


Asunto(s)
Diabetes Mellitus Tipo 2 , Insuficiencia Cardíaca , Adulto , Atención Ambulatoria , Gastos en Salud , Insuficiencia Cardíaca/epidemiología , Insuficiencia Cardíaca/terapia , Hospitalización , Humanos , Estados Unidos/epidemiología
3.
JACC Case Rep ; 3(10): 1264-1268, 2021 Aug 18.
Artículo en Inglés | MEDLINE | ID: mdl-34471875

RESUMEN

Cardiac aspergillomas are rare and associated with high mortality. We present a case of right ventricular cardiac aspergilloma in an asymptomatic renal transplant recipient. Intracavitary aspergilloma is an important consideration in evaluation of an intracardiac mass in an immunocompromised patient. (Level of Difficulty: Advanced.).

5.
J Neuroophthalmol ; 41(2): 239-245, 2021 06 01.
Artículo en Inglés | MEDLINE | ID: mdl-32235219

RESUMEN

BACKGROUND: Despite automated pupillometry's (AP) improved detection of relative afferent pupillary defects (RAPDs) compared with the Swinging Flashlight Test (SFT), AP remains uncommon in clinical practice. This study examined barriers to routine use of AP in evaluation of acute vision loss. METHODS: (1) Ophthalmologists and optometrists' perceptions of AP were captured via electronic survey. (2) Ophthalmologists were presented with clinical vignettes to assess their use of AP in clinical decision-making. (3) Patients presenting with decreased vision to an ophthalmology urgent care clinic underwent manual SFT and AP screening to evaluate ophthalmologists' perceptions of the device. RESULTS: Surveys indicated that clinicians were "neutral" to "somewhat likely" to use AP. In clinical vignettes, more physicians proceeded with workup for optic nerve pathology when presented with an RAPD by AP than SFT (77% vs 26%, P = 0.003). When SFT and AP results were discordant, more physicians proceeded with workup for optic nerve disease when AP was positive and SFT was negative than vice versa (61% vs 18%, P = 0.008). In the clinical study of 21 patients, 50% of RAPDs detected by AP were not detected by SFT, although ophthalmologists rated AP's usefulness as only "neutral" to "somewhat useful." CONCLUSION: Clinicians value pupillary examination and trust AP over SFT; however, widespread adoption and perceived value of AP may depend on its impact on clinical outcomes. Within a comprehensive diagnostic device, AP may be an important tool, but is not necessary to screen for optic nerve disease or evaluate acute vision loss.


Asunto(s)
Ceguera/etiología , Toma de Decisiones Clínicas/métodos , Técnicas de Diagnóstico Oftalmológico , Trastornos de la Pupila/complicaciones , Enfermedad Aguda , Adulto , Anciano , Anciano de 80 o más Años , Ceguera/diagnóstico , Femenino , Humanos , Masculino , Persona de Mediana Edad , Pupila , Trastornos de la Pupila/diagnóstico , Adulto Joven
6.
Neuroimage ; 58(1): 10-5, 2011 Sep 01.
Artículo en Inglés | MEDLINE | ID: mdl-21704173

RESUMEN

Expressive suppression is an emotion regulation strategy that requires interoceptive and emotional awareness. These processes both recruit the anterior insula. It is not known, however, whether increased use of expressive suppression is associated with increased anterior insula volume. In the present study, high-resolution anatomical MRI images were used to calculate insula volumes in a set of 50 healthy female subjects (mean 21.9 years) using both region of interest (ROI) and voxel-based morphometry (VBM) approaches. Participants also completed trait measures of expressive suppression usage, cognitive reappraisal usage, and negative emotional reactivity (the latter two served as control measures). As predicted, both ROI and VBM methods found that expressive suppression usage, but not negative affect and cognitive reappraisal, was positively related to anterior insula volume. These findings are consistent with the idea that trait patterns of emotion processing are related to brain structure.


Asunto(s)
Emociones/fisiología , Emoción Expresada/fisiología , Plasticidad Neuronal/fisiología , Corteza Prefrontal/anatomía & histología , Corteza Prefrontal/fisiología , Adolescente , Adulto , Femenino , Humanos , Procesamiento de Imagen Asistido por Computador , Individualidad , Imagen por Resonancia Magnética , Pruebas Neuropsicológicas , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...